Patents by Inventor Robert C. Doebele

Robert C. Doebele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds, compositions and methods for treating or preventing HER-driven drug-resistant cancers
    Patent number: 11426409
    Abstract: The present invention includes methods of treating or preventing HER-driven drug-resistant cancers. In certain embodiments, the cancer comprises lung cancer.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: August 30, 2022
    Assignee: The Regents of the University of Colorado
    Inventor: Robert C. Doebele
  • COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS
    Publication number: 20200268759
    Abstract: The present invention includes methods of treating or preventing HER-driven drug-resistant cancers. In certain embodiments, the cancer comprises lung cancer.
    Type: Application
    Filed: September 7, 2018
    Publication date: August 27, 2020
    Inventor: Robert C. DOEBELE
  • POINT MUTATIONS IN TRK INHIBITOR-RESISTANT CANCER AND METHODS RELATING TO THE SAME
    Publication number: 20170260589
    Abstract: Provided herein are methods of treating a subject having a cancer, methods of selecting a treatment for a subject having a cancer, methods of selecting a subject having a cancer for a treatment that does not include a Trk inhibitor, methods of determining the likelihood that a subject having a cancer will have a positive response to a treatment with a Trk inhibitor, methods of predicting the efficacy of a Trk inhibitor in a subject having cancer, methods of determining a subject's risk for developing a Trk inhibitor-resistant cancer, and methods of determining the presence of a Trk inhibitor-resistant cancer in a subject, based on the detection of a cell from a sample from the subject that has at least one of the the point mutations in NTRK1 and/or NTRK2 and/or NTRK3.
    Type: Application
    Filed: October 26, 2016
    Publication date: September 14, 2017
    Inventors: Nisha Nanda, Josh H. Bilenker, Robert C. Doebele, James F. Blake, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Steven W. Andrews
  • ACTIVATING NTRK1 GENE FUSIONS PREDICTIVE OF KINASE INHIBITOR THERAPY
    Publication number: 20170114415
    Abstract: Disclosed are markers, methods and assay systems for the identification of patients suspected of having cancer and/or cancer patients who are predicted to respond, or not respond to the therapeutic administration of specific chemotherapeutic regimens. Particularly, the invention provides a testing paradigm based on tumor cell samples to select cancer patients who will benefit from chemotherapy including one or more kinase inhibitor(s), as well as a paradigm to select cancer patients who will not benefit from such chemotherapy regimen.
    Type: Application
    Filed: June 1, 2015
    Publication date: April 27, 2017
    Inventors: Robert C. DOEBELE, Marileila Varella GARCIA, Anh T. LEE
  • METHODS FOR DIAGNOSIS AND TREATMENT OF CANCER
    Publication number: 20150218652
    Abstract: Disclosed are markers, methods and assay systems for the identification of patients suspected of having lung cancer and/or cancer patients who are predicted to respond, or not respond to the therapeutic administration of specific chemotherapeutic regimens. Particularly, the invention provides a testing paradigm based on tumor cell samples to select cancer patients who will benefit from chemotherapy including one or more kinase inhibitor(s), as well as a paradigm to select cancer patients who will not benefit from such chemotherapy regimen.
    Type: Application
    Filed: August 30, 2013
    Publication date: August 6, 2015
    Inventors: Robert C. Doebele, Marileila Varella Garcia, Anh T. Le